AU2508499A - Ligands of the cd47 antigen, agents binding the ligands of the cd47 antigen and uses thereof - Google Patents

Ligands of the cd47 antigen, agents binding the ligands of the cd47 antigen and uses thereof

Info

Publication number
AU2508499A
AU2508499A AU25084/99A AU2508499A AU2508499A AU 2508499 A AU2508499 A AU 2508499A AU 25084/99 A AU25084/99 A AU 25084/99A AU 2508499 A AU2508499 A AU 2508499A AU 2508499 A AU2508499 A AU 2508499A
Authority
AU
Australia
Prior art keywords
ligands
antigen
agents binding
binding
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU25084/99A
Inventor
Marie Sarfati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2508499A publication Critical patent/AU2508499A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AU25084/99A 1998-02-16 1999-02-16 Ligands of the cd47 antigen, agents binding the ligands of the cd47 antigen and uses thereof Abandoned AU2508499A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002226962A CA2226962A1 (en) 1998-02-16 1998-02-16 Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
CA2226962 1998-02-16
PCT/CA1999/000140 WO1999040940A1 (en) 1998-02-16 1999-02-16 Ligands of the cd47 antigen, agents binding the ligands of the cd47 antigen and uses thereof

Publications (1)

Publication Number Publication Date
AU2508499A true AU2508499A (en) 1999-08-30

Family

ID=4161989

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25084/99A Abandoned AU2508499A (en) 1998-02-16 1999-02-16 Ligands of the cd47 antigen, agents binding the ligands of the cd47 antigen and uses thereof

Country Status (3)

Country Link
AU (1) AU2508499A (en)
CA (1) CA2226962A1 (en)
WO (1) WO1999040940A1 (en)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053634A1 (en) * 1999-03-10 2000-09-14 Chugai Seiyaku Kabushiki Kaisha Single-stranded fv inducing apoptosis
EP1048299A1 (en) * 1999-04-28 2000-11-02 Faculteit der Geneeskunde van de Vrije Universiteit Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
DE19952960A1 (en) * 1999-11-03 2001-05-10 Mark Andre Freyberg Method for identifying anti-apoptotic compounds
EP1244707A1 (en) * 1999-11-30 2002-10-02 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antibodies against signal regulator proteins
GB9930706D0 (en) * 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
TWI242043B (en) * 2000-03-10 2005-10-21 Chugai Pharmaceutical Co Ltd Polypeptide inducing apoptosis
DE10109136A1 (en) * 2001-02-26 2002-09-12 Cytotools Gmbh Using inhibitor of thrombospondin-1 interaction for promoting wound healing, also for treating living skin replacements, inhibits apoptosis of wound-repair cells
US20040213792A1 (en) * 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
CA2652570A1 (en) * 2006-05-15 2007-11-22 Viral Logic Systems Technology Corp. Cd47 related compositions and methods for treating immunological diseases and disorders
AU2014201936B2 (en) * 2006-10-06 2016-07-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Prevention of tissue ischemia, related methods and compositions
CA3163418A1 (en) 2006-10-06 2008-05-22 Jeffrey S. Isenberg Prevention of tissue ischemia, related methods and compositions
AU2016238894B2 (en) * 2006-10-06 2017-11-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Prevention of tissue ischemia, related methods and compositions
EP2573112A1 (en) * 2007-10-11 2013-03-27 The Hospital For Sick Children Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
CA3108119C (en) 2008-01-15 2024-01-16 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
US11072655B2 (en) 2008-01-15 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
AU2009205665B2 (en) 2008-01-15 2013-12-05 The Board Of Trustees Of The Leland Stanford Junior University Methods for manipulating phagocytosis mediated by CD47
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
CA2747678A1 (en) * 2008-12-19 2010-06-24 Novartis Ag Soluble polypeptides for use in treating autoimmune and inflammatory disorders
US10907209B2 (en) * 2009-05-15 2021-02-02 University Health Network Compositions and methods for treating hematological cancers targeting the SIRPα CD47 interaction
SI2477648T1 (en) * 2009-09-15 2022-09-30 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
AU2013359167B2 (en) * 2012-12-12 2018-08-23 Arch Oncology, Inc. Therapeutic CD47 antibodies
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
DK3575326T3 (en) 2012-12-17 2022-05-30 Pf Argentum Ip Holdings Llc Treatment of CD47 + disease cells with SIRP ALFA-FC fusions
WO2014160183A1 (en) * 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
ES2765483T3 (en) 2013-09-18 2020-06-09 Univ Leland Stanford Junior Modulation of the spherocytosis pathways for the treatment of an atherosclerotic disease
PE20180778A1 (en) 2015-08-07 2018-05-07 Alexo Therapeutics Inc CONSTRUCTIONS WITH A SIRP-ALPHA DOMAIN OR ITS VARIANTS
NZ740686A (en) 2015-09-18 2021-12-24 Arch Oncology Inc Therapeutic cd47 antibodies
JP2018535692A (en) 2015-09-21 2018-12-06 エラスムス ユニバーシティ メディカル センターＥｒａｓｍｕｓ Ｕｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ Anti-CD47 antibody and method of use
CN114716552A (en) 2016-01-11 2022-07-08 四十七公司 Humanized, mouse or chimeric anti-CD47 monoclonal antibodies
CA3023802A1 (en) * 2016-05-10 2017-11-16 Sorbonne Universite Agents that activate cd47 and their use in the treatment of inflammation
JOP20190009A1 (en) 2016-09-21 2019-01-27 Alx Oncology Inc Antibodies against signal-regulatory protein alpha and methods of use
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
EP3658589B1 (en) 2017-07-26 2023-09-27 Forty Seven, Inc. Anti-sirp-alpha antibodies and related methods
EA039662B1 (en) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Antibodies specific to cd47 and pd-l1
CA3044097A1 (en) * 2017-11-10 2019-05-16 I-Mab Fusion proteins containing cd47 antibodies and cytokines
AU2018375375A1 (en) 2017-12-01 2020-05-28 Seagen Inc. CD47 antibodies and uses thereof for treating cancer
EP4129336A1 (en) 2018-02-12 2023-02-08 Forty Seven, Inc. Anti-cd47 agent-based treatment of cd20-positive cancer
CA3094098A1 (en) 2018-03-21 2019-09-26 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
WO2020243338A1 (en) 2019-05-31 2020-12-03 ALX Oncology Inc. Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor
US11795210B2 (en) 2019-07-16 2023-10-24 Gilead Sciences, Inc. HIV vaccines and methods of making and using
EP4045083B1 (en) 2019-10-18 2024-01-10 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
CA3153636A1 (en) 2019-10-31 2021-05-06 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
PE20230376A1 (en) 2019-12-24 2023-03-06 Carna Biosciences Inc DIACYL GLYCEROL KINASE MODULATING COMPOUNDS
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
US20220305100A1 (en) 2021-03-12 2022-09-29 Dcprime B.V. Methods of vaccination and use of cd47 blockade
TW202302145A (en) 2021-04-14 2023-01-16 美商基利科學股份有限公司 Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer
CN117377671A (en) 2021-06-23 2024-01-09 吉利德科学公司 Diacylglycerol kinase modulating compounds
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
KR20240005901A (en) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 Diacylglycerol Kinase Modulating Compounds
CN113501874B (en) * 2021-08-09 2022-03-11 生工生物工程（上海）股份有限公司 Anti-human CD47 protein antibody, detection kit and application thereof
TW202330504A (en) 2021-10-28 2023-08-01 美商基利科學股份有限公司 Pyridizin-3(2h)-one derivatives
US11919869B2 (en) 2021-10-29 2024-03-05 Gilead Sciences, Inc. CD73 compounds
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (en) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7 inhibitors
WO2023178181A1 (en) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (en) 2022-04-05 2023-12-01 美商基利科學股份有限公司 Combination therapy for treating colorectal cancer
TW202400138A (en) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057604A (en) * 1988-08-03 1991-10-15 Washington University Novel monoclonal antibodies
DE69132708T2 (en) * 1990-09-24 2002-06-20 Grace W R & Co Therapeutic use of peptides with thrombospondin-like activity
AU5430894A (en) * 1992-11-16 1994-06-08 Cymbus Bioscience Limited Diagnosis of eye disorders
WO1997027873A1 (en) * 1996-01-30 1997-08-07 Brigham & Women's Hospital, Inc. Antibodies for modulating cd47-mediated neutrophil transmigration

Also Published As

Publication number Publication date
CA2226962A1 (en) 1999-08-16
WO1999040940A1 (en) 1999-08-19

Similar Documents

Publication Publication Date Title
AU2508499A (en) Ligands of the cd47 antigen, agents binding the ligands of the cd47 antigen and uses thereof
AU9599498A (en) Biosensor
AU1290001A (en) Antibodies
AU2001271714A1 (en) B7-like polynucleotides, polypeptides, and antibodies
ZA98533B (en) Soluble CTLA4 mutant molecules and uses thereof.
AU4935000A (en) Antibodies
AU6059699A (en) Synthetic peptides, conjugation reagents and methods
GB9927332D0 (en) Novel antibody and uses thereof
AU1191001A (en) Plasminogen-like polynucleotides, polypeptides, and antibodies
AU3159499A (en) Antigen preparation and use
AU7337400A (en) B7-like polynucleotides, polypeptides, and antibodies
AU4606196A (en) Assay, receptor proteins and ligands
AU1582401A (en) Uteroglobin-like polynucleotides, polypeptides, and antibodies
AU7335400A (en) Attractin-like polynucleotides, polypeptides, and antibodies
HUP9800744A3 (en) Antibodies against fas-antigene
AU7104398A (en) Conopeptides auia, auib and auic
AU8682998A (en) Improvement in chemical analyses
AU8695298A (en) Compounds and uses thereof
AU6913100A (en) Notch receptor ligands and uses thereof
AU4159697A (en) Interaction trap assay, reagents and uses thereof
AU8919098A (en) Fumonosin resistance
AU7572198A (en) Tumor-associated antigen
AU8225398A (en) Biosensor materials and methods
HUP0202270A2 (en) Antitumor antibodies, proteins, and uses thereof
AU5137698A (en) Novel dna, novel protein, and novel antibody

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase